GCN5-ERKラκτηル化-リン酸化ループは乳酸駆動型がんの進行を増幅する
Bingsong Huang1,2, Mingpeng Jin3,4, Gaofeng Cui5
1Department of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Nature chemical biology
|January 13, 2026
まとめ
乳酸はERKのラκτηル化を介してMAPK経路を活性化することにより、がんを加速させます。この研究では、GCN5が責任酵素であること、およびKRAS変異型がんの腫瘍増殖を減少させるペプチド阻害剤を特定しました。
科学分野:
- 生化学
- 分子生物学
- がん研究
背景:
- ワールブルク効果は乳酸産生を増加させ、不明瞭なメカニズムを介してがん進行を促進します。
- がん進行における乳酸の役割は、その分子ドライバーの理解を必要とします。
研究 の 目的:
- 乳酸とがん進行を結びつける分子メカニズムを解明すること。
- 乳酸媒介のがん増殖に関与する主要な酵素と経路を特定すること。
- この経路を標的とする治療戦略を開発し、テストすること。
主な方法:
- 乳酸によるMAPK経路活性化の役割を調査しました。
- GCN5をERK(細胞外シグナル調節キナーゼ)のラκτηル化酵素として同定しました。
- ERKラκτηル化がERK-MEK相互作用と活性化に及ぼす影響を評価しました。
- がんモデルにおいてERKラκτηル化の細胞透過性ペプチド阻害剤を開発し、テストしました。
主要な成果:
- 乳酸はERKのラκτηル化を介してMAPK経路を活性化し、がんの進行を促進します。
- GCN5がERKのラκτηル化に関与するラκτηル化酵素として同定されました。
- 活性化されたERKはGCN5をリン酸化し、正のフィードバックループを形成します。
- K231におけるERKのラκτηル化はERK-MEK相互作用を弱め、ERKの二量体化と活性化を増強します。
- 開発されたペプチド阻害剤は、KRAS変異型がんモデルにおいて腫瘍増殖を損ないました。
結論:
- 乳酸は、ERK-GCN5ラκτηル化-リン酸化カスケードを介してがん進行を加速させます。
- ERKラκτηル化を標的とすることは、RAS-ERK駆動型がんの潜在的な治療戦略となります。
関連する概念動画
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
cAMP-dependent Protein Kinase Pathways
8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K

